General Pharmacology Practice Questions

Q: A patient received a placebo therapy, and another patient received a new drug. Given the following comparative data, what classes of drugs were likely administered? Placebo: Heart rate 72, SBP 110, DBP 80, Cardiac output 5. New Drug: Heart rate 86, SBP 150, DBP 68, Cardiac output 6.

Alpha-1 antagonist and Beta agonist. ### Explanation To identify the drug class, we must analyze the hemodynamic changes compared to the placebo baseline: 1. **Heart Rate (72 → 86):** An increase (tachycardia) suggests **Beta-1 stimulation** or a reflex response. 2. **Systolic BP (110 → 150):** A significant increase indicates increased **Cardiac Output (CO)** and/or stroke volume, primarily mediated by **Beta-1 receptors**. 3. **Diastolic BP (80 → 68):** A decrease indicates a reduction in **Total Peripheral Resistance (TPR)**. This occurs via **Alpha-1 blockade** or **Beta-2 stimulation** (vasodilation). 4. **Cardiac Output (5 → 6):** An increase confirms positive inotropic and chronotropic effects (**Beta-1 effect**). **Why Option A is Correct:** A **Beta agonist** (like Isoprenaline or Dobutamine) explains the increased HR, SBP, and CO. An **Alpha-1 antagonist** (like Phentolamine) explains the drop in DBP by preventing vasoconstriction, leading to decreased peripheral resistance. **Analysis of Incorrect Options:** * **B & C (Alpha-1 agonist):** Alpha-1 agonists cause potent vasoconstriction, which would **increase** DBP significantly and often cause reflex bradycardia. * **D (Beta agonist + Beta-2 agonist):** While this would increase CO and decrease DBP, the combination lacks the specific Alpha-antagonism often tested in "mixed effect" scenarios. However, the primary differentiator in NEET-PG patterns is that Alpha-1 agonists are excluded due to the *drop* in DBP. **NEET-PG High-Yield Pearls:** * **SBP** is primarily determined by **Cardiac Output** (Beta-1). * **DBP** is primarily determined by **Peripheral Resistance** (Alpha-1 and Beta-2). * **Pulse Pressure (SBP - DBP):** Widens significantly with Beta-1 stimulation combined with Alpha-1 blockade or Beta-2 stimulation. * **Isoprenaline** (Non-selective Beta agonist) typically increases SBP, increases HR, and decreases DBP—mimicking the "New Drug" profile in this question.

Q: In recommending treatment for a patient with carcinoid syndrome, which of the following medications would NOT be considered?

Sumatriptan. **Explanation** **Carcinoid syndrome** is characterized by the excessive secretion of serotonin (5-HT) from neuroendocrine tumors [4]. Management focuses on blocking serotonin receptors or inhibiting its release. **Why Sumatriptan is the Correct Answer:** Sumatriptan is a **5-HT$_{1B/1D}$ receptor agonist** used primarily for the acute treatment of migraines [2],[3]. In carcinoid syndrome, the goal is to **antagonize** the effects of excess serotonin. Administering a serotonin agonist like Sumatriptan would be counter-productive and is not indicated in the management of this syndrome. **Analysis of Incorrect Options:** * **Cyproheptadine:** A potent **5-HT$_2$ receptor antagonist** (also has H$_1$ blocking properties). It is frequently used to control the diarrhea and flushing associated with carcinoid syndrome. * **Ketanserin:** A selective **5-HT$_{2A}$ antagonist** that also blocks $\alpha_1$-adrenoceptors. It is effective in managing the vasomotor symptoms (flushing) and hypertension in these patients. * **Methysergide:** An ergot derivative that acts as a **5-HT$_{2A/2C}$ antagonist**. While effective for carcinoid symptoms, its long-term use is limited by the risk of retroperitoneal and subendocardial fibrosis [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** **Octreotide** (a long-acting Somatostatin analogue) is the gold standard for controlling symptoms and reducing 5-HIAA levels in carcinoid syndrome. * **Diagnostic Marker:** 24-hour urinary **5-HIAA** (5-Hydroxyindoleacetic acid) is the primary metabolite used for diagnosis. * **Pellagra Risk:** Patients may develop Niacin (Vitamin B3) deficiency because dietary Tryptophan is diverted toward massive Serotonin production rather than Niacin synthesis.

Q: Which of the following drugs is not converted into an active metabolite?

Lisinopril. The correct answer is **Lisinopril**. **1. Why Lisinopril is correct:** Most ACE inhibitors (like Enalapril, Ramipril, and Perindopril) are **prodrugs** [2], meaning they are inactive in their parent form and must be converted by hepatic esterases into their active “–at” forms (e.g., Enalaprilat). However, **Lisinopril** and **Captopril** are the two notable exceptions; they are active in their parent form and do not require hepatic metabolism for activation [1]. This makes Lisinopril particularly useful in patients with liver dysfunction. **2. Why the other options are incorrect:** * **Fluoxetine:** This SSRI is metabolized in the liver to **Norfluoxetine**, which is a potent active metabolite with a significantly longer half-life than the parent drug. * **Cyclophosphamide:** This is a classic **prodrug**. It is inactive until it is metabolized by hepatic cytochrome P450 enzymes (specifically CYP2B6) into active metabolites like **phosphoramide mustard** (the alkylating agent) and acrolein (the metabolite responsible for hemorrhagic cystitis). * **Diazepam:** This benzodiazepine has several long-acting active metabolites, including **Desmethyldiazepam (Nordiazepam)**, Oxazepam, and Temazepam, which contribute to its prolonged duration of action. **3. High-Yield NEET-PG Clinical Pearls:** * **ACE Inhibitor Exceptions:** Remember the mnemonic: *“All ACE inhibitors are prodrugs except **C**aptopril and **L**isinopril”* (**C**an **L**ive). * **Lisinopril Excretion:** Since it is not metabolized by the liver, it is excreted unchanged by the kidneys. Dose adjustment is crucial in renal failure. * **Prodrugs to remember:** Levopa (to Dopamine), Terfenadine (to Fexofenadine), and Clopidogrel (activated by CYP2C19).

Q: Which of the following drugs requires therapeutic drug monitoring?

Phenytoin. **Explanation:** **Phenytoin** is the correct answer because it exhibits **zero-order (non-linear) kinetics** at therapeutic or high-therapeutic concentrations. This means the metabolic enzymes (CYP2C9/19) become saturated, and even a small increase in dose can lead to a disproportionately large increase in plasma concentration, resulting in toxicity. Additionally, it has a **narrow therapeutic index** (10–20 µg/mL), making Therapeutic Drug Monitoring (TDM) essential to ensure efficacy and avoid adverse effects like ataxia and nystagmus. **Why the other options are incorrect:** * **Warfarin:** While it has a narrow therapeutic index, it is monitored using a functional physiological marker—the **INR (International Normalized Ratio)**—rather than plasma drug levels. TDM is generally reserved for drugs where a simple physiological effect cannot be easily measured. * **Metformin:** It has a wide safety margin and its efficacy is monitored via clinical markers like blood glucose and HbA1c levels. * **Propranolol:** It is a beta-blocker whose effect is easily monitored by measuring the patient’s heart rate and blood pressure. **High-Yield Clinical Pearls for NEET-PG:** * **Indications for TDM:** Drugs with narrow therapeutic index, non-linear kinetics, high inter-individual variation, or when toxicity is difficult to distinguish from the disease (e.g., Digoxin). * **Common TDM Drugs:** Lithium, Digoxin, Theophylline, Aminoglycosides (Gentamicin), Vancomycin, Cyclosporine, and Antiepileptics (Phenytoin, Carbamazepine). * **Exceptions:** Drugs like **Warfarin (INR)**, **Heparin (aPTT)**, and **Antihypertensives** do NOT require TDM because their pharmacological effect is easily quantifiable.

Q: You have a 1:10,000 adrenaline solution. If you want to inject 1 mg of adrenaline, how much volume of this solution should be injected?

10 ml. **Explanation:** The core concept here is understanding **ratio expressions** of drug concentrations. In pharmacology, a ratio of **1:X** means **1 gram of drug in X ml of solution**. 1. **Calculating the Correct Answer (A):** * A **1:10,000** solution means **1 gram** of adrenaline is present in **10,000 ml** of solution. * Since 1 gram = 1,000 mg, the ratio is **1,000 mg in 10,000 ml**. * By simplifying (dividing both sides by 1,000), we get **1 mg in 10 ml**. * Therefore, to administer 1 mg of adrenaline, you must inject **10 ml**. 2. **Why Incorrect Options are Wrong:** * **B (1 ml):** This would contain only 0.1 mg of adrenaline. This is the volume used for a 1:1,000 concentration (standard IM dose) [1]. * **C (100 ml):** This would contain 10 mg of adrenaline, which is a massive overdose. * **D (0.01 ml):** This is an insignificantly small volume containing only 0.001 mg. **NEET-PG High-Yield Clinical Pearls:** * **1:1,000 (1 mg/ml):** Used for **Intramuscular (IM)** injection in Anaphylaxis [1]. * **1:10,000 (0.1 mg/ml):** Used for **Intravenous (IV)** or Intraosseous administration during Cardiac Arrest (ACLS protocols). * **1:100,000:** Often used as a vasoconstrictor mixed with local anesthetics (e.g., Lignocaine). * **Rule of Thumb:** Always remember that "1:1,000" equals "1 mg per 1 ml." Any further dilution (like 1:10,000) simply adds a zero to the volume required for 1 mg.

Q: Basiliximab is?

Anti CD25 monoclonal antibody. **Explanation:** **Basiliximab** is a chimeric monoclonal antibody that acts as a potent immunosuppressant. Its mechanism of action involves binding specifically to the **alpha subunit (CD25)** of the **Interleukin-2 (IL-2) receptor** expressed on the surface of activated T-lymphocytes. By competitively inhibiting the binding of IL-2 to its receptor, Basiliximab prevents T-cell proliferation and activation, which are critical steps in the cellular immune response against transplanted organs. **Analysis of Options:** * **Option A (Anti-CD3):** This refers to **Muromonab-CD3 (OKT3)**. It targets the CD3 complex on all T-cells, causing profound depletion. It is rarely used now due to "cytokine release syndrome." * **Option B (Correct):** Basiliximab (and Daclizumab) are specific **IL-2 receptor antagonists (Anti-CD25)**. * **Option C (IL-1 Receptor Antagonist):** This describes **Anakinra**, primarily used in the treatment of Rheumatoid Arthritis and Cryopyrin-associated periodic syndromes (CAPS). * **Option D (TNF-alpha Inhibitor):** This group includes drugs like **Infliximab, Adalimumab, and Etanercept**, used for autoimmune conditions like Crohn’s disease and Rheumatoid Arthritis. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Indication:** Prophylaxis of **acute organ rejection** in renal transplantation (induction therapy). * **Key Advantage:** Unlike Muromonab-CD3, Basiliximab does not cause significant cytokine release syndrome because it only targets *activated* T-cells. * **Mnemonic:** "Basiliximab and Daclizumab are **25** letters combined" (to remember **CD25**). * **Chimeric vs. Humanized:** Basiliximab is **chimeric** (contains "-xi-"), whereas Daclizumab is **humanized** (contains "-zu-").

Q: Which of the following drugs is associated with tachyphylaxis?

Ephedrine. **Explanation:** **Tachyphylaxis** is a pharmacological phenomenon characterized by a rapid decrease in response to a drug after repeated administration over a short period. It is a form of "acute tolerance" that cannot be overcome by increasing the dose. **Why Ephedrine is the Correct Answer:** Ephedrine is a classic example of a drug that exhibits tachyphylaxis. It acts via a **mixed mechanism**: it directly stimulates adrenergic receptors and, more importantly, **indirectly** causes the release of stored norepinephrine (NE) from sympathetic nerve terminals. With repeated, frequent dosing, the readily releasable pools of NE become depleted. Once these stores are exhausted, subsequent doses of ephedrine produce a progressively diminishing effect, as there is no neurotransmitter left to release. **Analysis of Incorrect Options:** * **Dopamine:** While it is a catecholamine, it is primarily metabolized by MAO and COMT and does not typically demonstrate the rapid depletion-related tachyphylaxis seen with ephedrine. * **Haloperidol:** This is an antipsychotic (D2 blocker). Chronic use leads to **supersensitivity** or up-regulation of receptors (leading to tardive dyskinesia), rather than rapid tachyphylaxis. * **Propranolol:** As a beta-blocker, long-term use leads to **up-regulation** of receptors. Abrupt withdrawal can cause rebound hypertension or tachycardia, which is the opposite of tachyphylaxis. **High-Yield Clinical Pearls for NEET-PG:** * **Common drugs showing tachyphylaxis:** Ephedrine, Tyramine, Amphetamine, Nitroglycerin, Nicotine, and Nasal decongestants (e.g., Oxymetazoline). * **Mechanism:** For indirect sympathomimetics (Ephedrine/Amphetamine), the mechanism is **depletion of neurotransmitter stores**. For Nitrates, it involves the depletion of free sulfhydryl (-SH) groups. * **Distinction:** Unlike "Tolerance," which develops slowly (days/weeks), Tachyphylaxis develops **rapidly** (minutes/hours).

Q: Which microsomal enzyme is involved in the metabolism of omeprazole?

CYP 2C19. **Explanation:** **Omeprazole**, a Proton Pump Inhibitor (PPI), is primarily metabolized in the liver by the cytochrome P450 system. The major enzyme responsible for its metabolism is **CYP2C19**, which converts omeprazole to 5-hydroxyomeprazole. A smaller portion is metabolized by CYP3A4 to omeprazole sulfone. **Analysis of Options:** * **CYP2C19 (Correct):** This is the principal enzyme for omeprazole metabolism. Genetic polymorphism of CYP2C19 is clinically significant; "poor metabolizers" (common in Asian populations) exhibit higher plasma concentrations and better therapeutic responses to PPIs compared to "rapid metabolizers." * **CYP2A:** This subfamily (specifically CYP2A6) is primarily involved in the metabolism of nicotine and coumarin, not PPIs. * **CYP2C8:** This enzyme is involved in the metabolism of drugs like paclitaxel, amodiaquine, and pioglitazone. * **CYP2B:** Specifically CYP2B6, this enzyme is responsible for metabolizing drugs such as bupropion and efavirenz. **High-Yield Clinical Pearls for NEET-PG:** 1. **Drug Interaction:** Omeprazole is a known **inhibitor of CYP2C19**. It can decrease the activation of **Clopidogrel** (a prodrug that requires CYP2C19 for conversion to its active form), potentially increasing the risk of cardiovascular events. 2. **Stereoisomerism:** **Esomeprazole** (the S-isomer of omeprazole) is less dependent on CYP2C19, leading to more predictable bioavailability and fewer drug interactions. 3. **Other CYP2C19 Substrates:** Phenytoin, Voriconazole, and Warfarin (minor).

Question 1

A patient received a placebo therapy, and another patient received a new drug. Given the following comparative data, what classes of drugs were likely administered? Placebo: Heart rate 72, SBP 110, DBP 80, Cardiac output 5. New Drug: Heart rate 86, SBP 150, DBP 68, Cardiac output 6.

Accepted Answer

Alpha-1 antagonist and Beta agonist

Answer

Alpha-1 agonist and M3 agonist

Answer

Alpha-1 agonist and Beta agonist

Answer

Beta agonist and Beta-2 agonist

Question 2

In recommending treatment for a patient with carcinoid syndrome, which of the following medications would NOT be considered?

Accepted Answer

Sumatriptan

Answer

Cyproheptadine

Answer

Ketanserin

Answer

Methysergide

Question 3

Which of the following drugs is not converted into an active metabolite?

Accepted Answer

Lisinopril

Answer

Fluoxetine

Answer

Cyclophosphamide

Answer

Diazepam

Question 4

Which of the following drugs requires therapeutic drug monitoring?

Accepted Answer

Phenytoin

Answer

Warfarin

Answer

Metformin

Answer

Propranolol

Question 5

You have a 1:10,000 adrenaline solution. If you want to inject 1 mg of adrenaline, how much volume of this solution should be injected?

Accepted Answer

10 ml

Answer

1 ml

Answer

100 ml

Answer

0.01 ml

Question 6

Basiliximab is?

Accepted Answer

Anti CD25 monoclonal antibody

Answer

Anti CD3 monoclonal antibody

Answer

IL1 receptor antagonist

Answer

TNF alpha inhibitor

Question 7

Which of the following drugs is associated with tachyphylaxis?

Accepted Answer

Ephedrine

Answer

Dopamine

Answer

Haloperidol

Answer

Propranolol

Question 8

Which microsomal enzyme is involved in the metabolism of omeprazole?

Accepted Answer

CYP 2C19

Answer

CYP 2A

Answer

CYP 2C8

Answer

CYP 2B

Question 9

Which of the following statements is true about first-order kinetics?

Accepted Answer

The rate of elimination increases with an increase in drug concentration and decreases with a decrease in drug concentration.

Answer

Very few drugs follow first-order kinetics.

Answer

The half-life (t1/2) is constant.

Answer

Salicylates follow first-order kinetics throughout their therapeutic ranges.

Question 10

Good practice is NOT needed in which phase of a clinical trial?

Accepted Answer

Preclinical stage

Answer

Phase 2

Answer

Phase 3

Answer

Phase 4

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?